13F Holdings
中文EN

ADXN Addex Therapeutics Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1574232 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-74.9%
TTM net income YoY166.8%
TTM EPS YoY150.0%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-681.8%
Net margin1,746.0%
FCF margin-1,330.1%
EBITDA margin—

Returns

ROE130.4%
ROA92.1%
ROIC (approx.)-120.4%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets9.4%
Debt / equity0.00x
Current ratio4.42x
Interest coverage-1,712.39x

Cash quality & payout

Operating cash flow / net income-0.76x
Accruals ratio162.3%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31FY2020*2020-12-31
Income statement
Revenue404,1021.61M1.42M2.92M3.61M
R&D expense854,3051.19M8.24M12.84M10.37M
SG&A expense2.31M2.67M3.74M5.82M5.75M
Operating income-2.76M-2.24M-10.54M-15.51M-12.24M
Interest expense1,6091,6442,06839,14650,460
Pretax income-4.91M-2.50M-10.80M-15.35M-12.86M
Income tax00000
Net income7.06M-10.56M-20.80M-15.35M-12.86M
EPS (basic)0.07-0.14-0.46-0.45-0.48
EPS (diluted)0.07-0.14-0.46-0.45-0.48
Balance sheet
Cash & equivalents3.34M3.87M6.96M20.48M18.70M
Receivables15,513110,361416,875164,78568,373
Current assets3.54M4.23M7.83M21.94M19.49M
PP&E, netmay include right-of-use assets (IFRS)1,13122,60441,12172,11167,760
Total assets10.68M4.64M8.28M22.54M20.18M
Current liabilities802,0932.89M3.28M4.13M3.62M
Short-term debt00000
Long-term debt00000
Total debt00000
Total liabilities1.00M3.50M3.37M5.61M5.57M
Shareholders' equity9.68M1.15M4.91M16.93M14.61M
Net debt-3.34M-3.87M-6.96M-20.48M-18.70M
Shares outstanding128.29M125.20M77.13M37.90M27.12M
Cash flow statement
Operating cash flow-5.37M-7.99M-16.44M-14.71M-12.18M
Capital expenditure1,2736,84258131,54959,414
Free cash flow-5.37M-8.00M-16.44M-14.74M-12.24M
Investing cash flow4.65M-6,8422,972-30,313-59,414
Financing cash flow104,9185.26M3.10M16.40M46,399
Stock-based compensation502,9641.79M3.68M1.18M1.18M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.